Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases
Kisqali (ribociclib) combined with endocrine therapy prolongs the overall survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer with visceral metastases (in the soft internal organs), data from two Phase 3 clinical trials show. That finding was presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 29–31 in a virtual format. The presentation was titled “Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.”  Kisqali is a
Subscribe or to access all post and page content.